- ICH GCP
- Registre américain des essais cliniques
- Essai clinique NCT05270668
Étude de phase 2 sur l'innocuité et l'efficacité de PRA023 chez des sujets atteints de sclérodermie systémique associée à une maladie pulmonaire interstitielle (SSc-ILD) (ATHENA-SSc-ILD)
Une étude en double aveugle, randomisée et contrôlée par placebo pour évaluer l'efficacité et l'innocuité de PRA023 chez des sujets atteints de sclérodermie systémique associée à une maladie pulmonaire interstitielle (SSc-ILD)
The purpose of this study is to assess the safety and efficacy of tulisokibart in participants with SSc-ILD.
Aperçu de l'étude
Statut
Intervention / Traitement
Type d'étude
Inscription (Réel)
Phase
- Phase 2
Contacts et emplacements
Lieux d'étude
-
-
Baden-Wurttemberg
-
Freiburg im Breisgau, Baden-Wurttemberg, Allemagne, 79106
- Universitaetsklinikum Freiburg ( Site 4152)
-
-
Hesse
-
Bad Nauheim, Hesse, Allemagne, 61231
- Kerckhoff-Klinik-Forschungs-GmbH ( Site 4153)
-
-
Mecklenburg-Vorpommern
-
Hohenfelde B Bad Doberan, Mecklenburg-Vorpommern, Allemagne, 18209
- Rheumazentrum am Krankenhaus Bad Doberan ( Site 4150)
-
-
North Rhine-Westphalia
-
Cologne, North Rhine-Westphalia, Allemagne, 50937
- Universitaetsklinikum Koeln ( Site 4151)
-
-
-
-
Buenos Aires
-
CABA, Buenos Aires, Argentine, C1426ABP
- Consultorios Médicos Dr. Doreski ( Site 4800)
-
Munro, Buenos Aires, Argentine, 1605
- Clínica Privada Independencia ( Site 4802)
-
-
Córdoba Province
-
Río Cuarto, Córdoba Province, Argentine, 5800
- Centro de Investigación Instituto Médico Río Cuarto ( Site 4801)
-
-
Santa Fe Province
-
Rosario, Santa Fe Province, Argentine, S2000CEJ
- Instituto Medico de la Fundacion Estudios Clinicos ( Site 4803)
-
-
-
-
South Australia
-
Adelaide, South Australia, Australie, 5000
- Royal Adelaide Hospital ( Site 4050)
-
-
Victoria
-
Melbourne, Victoria, Australie, 3065
- St Vincents Hospital Melbourne ( Site 4051)
-
-
-
-
Oost-Vlaanderen
-
Ghent, Oost-Vlaanderen, Belgique, 9000
- UZ Gent ( Site 4401)
-
-
Vlaams-Brabant
-
Leuven, Vlaams-Brabant, Belgique, 3000
- UZ Leuven ( Site 4402)
-
-
Wallonne, Region
-
Liège, Wallonne, Region, Belgique, 4000
- CHU de Liege ( Site 4400)
-
-
-
-
Alberta
-
Edmonton, Alberta, Canada, T6G 1W9
- University Of Alberta Hospital ( Site 4702)
-
-
Ontario
-
London, Ontario, Canada, N6A 4V2
- St. Joseph's Health Care London ( Site 4701)
-
Toronto, Ontario, Canada, M5T 3L9
- Mount Sinai Hospital [Toronto, Canada] ( Site 4700)
-
-
-
-
Araucania
-
Temuco, Araucania, Chili, 4780000
- Centro de especialidades médicas Vanguardia ( Site 4850)
-
-
Region M. de Santiago
-
Santiago, Region M. de Santiago, Chili, 8320000
- BIOCINETIC Ltda ( Site 4854)
-
Santiago, Region M. de Santiago, Chili, 8330034
- Centro de Investigacion Clinica UC CICUC ( Site 4855)
-
Santiago, Region M. de Santiago, Chili, 8420383
- Centro Internacional de Estudios Clinicos CIEC ( Site 4851)
-
Vitacura, Region M. de Santiago, Chili, 7640881
- Clinica Dermacross ( Site 4853)
-
-
Valparaiso
-
Viña del Mar, Valparaiso, Chili, 2520598
- ONCOCENTRO APYS ( Site 4852)
-
-
-
-
-
Barcelona, Espagne, 08035
- Hospital Universitario Vall d'Hebron - PPDS ( Site 4107)
-
Barcelona, Espagne, 08041
- Hospital Santa Creu i Sant Pau ( Site 4102)
-
Madrid, Espagne, 28034
- Hospital Universitario Ramon y Cajal ( Site 4101)
-
Málaga, Espagne, 29009
- Hospital Regional Universitario de Malaga ( Site 4104)
-
Valencia, Espagne, 46017
- Hospital Universitario Doctor Peset ( Site 4103)
-
Zaragoza, Espagne, 50009
- Hospital Clinico Universitario Lozano Blesa ( Site 4100)
-
-
Catalonia
-
Barcelona, Catalonia, Espagne, 08036
- HOSPITAL CLÍNIC DE BARCELONA ( Site 4105)
-
-
Madrid, Comunidad de
-
Madrid, Madrid, Comunidad de, Espagne, 28041
- Hospital Universitario 12 de Octubre ( Site 4106)
-
-
Principality of Asturias
-
Oviedo, Principality of Asturias, Espagne, 33011
- Hospital Central de Asturias ( Site 4109)
-
-
-
-
-
Paris, France, 75679
- Hopital Cochin ( Site 4203)
-
-
Nord
-
Bordeaux, Nord, France, 33076
- CHU de Bordeaux. Hopital Pellegrin ( Site 4202)
-
Lille, Nord, France, 59000
- Hôpital Claude Huriez ( Site 4200)
-
-
-
-
-
Budapest, Hongrie, 1023
- Budai Irgalmasrendi Korhaz ( Site 4252)
-
Budapest, Hongrie, 1097
- Del-pesti Centrumkorhaz Orszagos Hematologiai es Infektologiai Intezet ( Site 4253)
-
Debrecen, Hongrie, 4032
- Debreceni Egyetem Klinikai Kozpont ( Site 4251)
-
-
Baranya
-
Pécs, Baranya, Hongrie, 7632
- Pecsi Tudomanyegyetem AOK ( Site 4250)
-
-
-
-
-
Haifa, Israël, 3109601
- Rambam Medical Center ( Site 4601)
-
Kfar Saba, Israël, 4428164
- Meir Medical Center. ( Site 4604)
-
Nahariya, Israël, 2210001
- Galilee Medical Center ( Site 4602)
-
Petach Tikvah, Israël, 49100
- Rabin Medical Center ( Site 4603)
-
Ramat Gan, Israël, 5265601
- Sheba Medical Center ( Site 4605)
-
Tel Aviv, Israël, 6423906
- Tel Aviv Sourasky Medical Center ( Site 4606)
-
-
-
-
-
Florence, Italie, 50141
- Azienda Ospedaliera Universitaria Careggi ( Site 4301)
-
Genova, Italie, 16132
- Ospedale Policlinico San Martino ( Site 4305)
-
Milan, Italie, 20122
- IRCCS Osp. Maggiore Policlinico ( Site 4306)
-
Milan, Italie, 20132
- Ospedale San Raffaele di Milano ( Site 4307)
-
Pavia, Italie, 27100
- Fondazione IRCCS Policlinico San Matteo ( Site 4303)
-
Reggio Emilia, Italie, 42123
- Arcispedale Santa Maria Nuova ( Site 4300)
-
Roma, Italie, 00161
- Azienda Policlinico Umberto I ( Site 4302)
-
-
Piedmont
-
Turin, Piedmont, Italie, 10126
- A.O.U. Citta della Salute e della Scienza di Torino ( Site 4304)
-
-
-
-
Jalisco
-
Guadalajara, Jalisco, Mexique, 44670
- PanAmerican Clinical Research - Guadalajara ( Site 4900)
-
-
Mexico City
-
Mexico City, Mexico City, Mexique, 31000
- Centro de Investigación y Tratamiento Reumatológico S.C ( Site 4902)
-
-
-
-
-
Oslo, Norvège, 0372
- Oslo Universitetssykehus HF. Rikshospitalet ( Site 4350)
-
-
-
-
Gelderland
-
Nijmegen, Gelderland, Pays-Bas, 6500 HB
- Radboud University Medical Center ( Site 4650)
-
-
-
-
Greater Poland Voivodeship
-
Poznan, Greater Poland Voivodeship, Pologne, 61-293
- Twoja Przychodnia Poznanskie Centrum Medyczne ( Site 4452)
-
Warszawa, Greater Poland Voivodeship, Pologne, 02-637
- Narodowy Instytut Geriatrii Reumatologii i Rehabilitacji im.Prof. El. Reicher-ul.Spartanska 1 ( Site
-
-
Kuyavian-Pomeranian Voivodeship
-
Bydgoszcz, Kuyavian-Pomeranian Voivodeship, Pologne, 85-168
- Szpital Uniwersytecki nr 2 im. dr Jana Biziela w Bydgoszczy ( Site 4454)
-
-
Lower Silesian Voivodeship
-
Wroclaw, Lower Silesian Voivodeship, Pologne, 52-416
- Centrum Medyczne Oporow ( Site 4455)
-
-
Masovian Voivodeship
-
Warsaw, Masovian Voivodeship, Pologne, 02-691
- Centrum Medyczne Reuma Park NZOZ ( Site 4450)
-
-
Podlaskie Voivodeship
-
Bialystok, Podlaskie Voivodeship, Pologne, 15-276
- Uniwersytecki Szpital Kliniczny w Bialymstoku - Marii Sklodowskiej-Curie 24A ( Site 4451)
-
-
Silesian Voivodeship
-
Bytom, Silesian Voivodeship, Pologne, 41-902
- Szpital Specjalistyczny nr 1 w Bytomiu ( Site 4453)
-
-
-
-
-
Lima, Pérou, 15023
- Instituto de Ginecologia y Reproduccion ( Site 4952)
-
-
-
-
-
Leeds, Royaume-Uni, LS7 4SA
- Chapel Allerton Hospital ( Site 4551)
-
-
London, City of
-
London, London, City of, Royaume-Uni, NW3 2QG
- Royal Free Hospital ( Site 4550)
-
-
-
-
-
Geneva, Suisse, 1211
- Hopitaux Universitaires de Geneve HUG ( Site 4503)
-
Zurich, Suisse, 8091
- Universitaetsspital Zuerich ( Site 4500)
-
-
Canton of Bern
-
Bern, Canton of Bern, Suisse, 3010
- Inselspital Bern ( Site 4502)
-
-
Canton of St. Gallen
-
Sankt Gallen, Canton of St. Gallen, Suisse, 9007
- Kantonsspital St. Gallen ( Site 4501)
-
-
-
-
-
Kyiv, Ukraine, 02091
- Medical Center OK!Clinic+LLC International Institute of Clinical Research ( Site 4753)
-
Kyiv, Ukraine, 2081
- Institute of Rheumatology LLC ( Site 4752)
-
-
Kyivska Oblast
-
Kyiv, Kyivska Oblast, Ukraine, 02125
- Kyiv City Clinical Hospital # 3 ( Site 4754)
-
-
Ternopil Oblast
-
Ternopil, Ternopil Oblast, Ukraine, 46002
- ME "Ternopil Regional Clinical Hospital of Ternopil Regional Council" ( Site 4750)
-
-
Vinnytsia Oblast
-
Vinnytsia, Vinnytsia Oblast, Ukraine, 21018
- Vinnytsia Nat Med University n.a.M.Pyrogov,City Clinical Hospital #1 ( Site 4751)
-
-
-
-
Arizona
-
Phoenix, Arizona, États-Unis, 85054
- Mayo Clinic - Scottsdale ( Site 4014)
-
-
California
-
Los Angeles, California, États-Unis, 90045
- Pacific Arthritis Care Center ( Site 4008)
-
Los Angeles, California, États-Unis, 90048
- Cedars Sinai Medical Center ( Site 4010)
-
Los Angeles, California, États-Unis, 90095-1670
- UCLA School of Medicine ( Site 4006)
-
Palo Alto, California, États-Unis, 94304
- Stanford Health Care ( Site 4009)
-
-
Colorado
-
Denver, Colorado, États-Unis, 80206
- National Jewish Health Medical Center ( Site 4015)
-
-
Connecticut
-
New Haven, Connecticut, États-Unis, 06519
- Yale University ( Site 4017)
-
-
District of Columbia
-
Washington D.C., District of Columbia, États-Unis, 20007
- MedStar Georgetown University Hospital ( Site 4005)
-
-
Maryland
-
Baltimore, Maryland, États-Unis, 21224
- Johns Hopkins Asthma and Allergy Center [Baltimore, MD] ( Site 4018)
-
-
Massachusetts
-
Boston, Massachusetts, États-Unis, 02114
- Massachusetts General Hospital ( Site 4003)
-
Boston, Massachusetts, États-Unis, 02118
- Boston University School of Medicine ( Site 4021)
-
-
Michigan
-
Ann Arbor, Michigan, États-Unis, 48109
- University of Michigan Hospital ( Site 4001)
-
-
New Jersey
-
New Brunswick, New Jersey, États-Unis, 08901
- Rutgers Robert Wood Johnson Medical School ( Site 4013)
-
-
New York
-
New York, New York, États-Unis, 10021
- Hospital For Special Surgery ( Site 4020)
-
-
Ohio
-
Cleveland, Ohio, États-Unis, 44195
- Cleveland Clinic Foundation ( Site 4019)
-
Toledo, Ohio, États-Unis, 43614
- University of Toledo Medical Center ( Site 4002)
-
-
Pennsylvania
-
Pittsburgh, Pennsylvania, États-Unis, 15213
- University of Pittsburgh Medical Center ( Site 4016)
-
-
South Carolina
-
Charleston, South Carolina, États-Unis, 29425
- Medical University of South Carolina - PPDS ( Site 4004)
-
-
Texas
-
Houston, Texas, États-Unis, 77030
- UT Physicians Rheumatology ( Site 4007)
-
-
Wisconsin
-
Milwaukee, Wisconsin, États-Unis, 53226
- Froedtert and Medical College of Wisconsin ( Site 4012)
-
-
Critères de participation
Critère d'éligibilité
Âges éligibles pour étudier
Accepte les volontaires sains
Sexes éligibles pour l'étude
La description
Inclusion Criteria:
- Has confirmed diagnosis of systemic sclerosis with onset of disease ≤ 5 years ago.
- Has diffuse cutaneous scleroderma
- Has systemic sclerosis related interstitial lung disease confirmed by HRCT
- FVC ≥ 45% of predicted normal
- Diffusing capacity of lung for carbon monoxide (DLCO)≥ 45% of predicted normal
- If on background therapy, meets stable dosing requirements for nintedanib, mycophenolate mofetil (MMF), methotrexate (MTX) OR azathioprine, and corticosteroids
- Women of childbearing potential are eligible to participate if not pregnant or breastfeeding and either willing to use an acceptable contraceptive method or sexually abstinent
- Able to provide written informed consent and understand and comply with the requirements of the study
Exclusion Criteria:
- Has an airway obstruction per pulmonary function test (PFT) or clinically significant pulmonary arterial hypertension
- Has current clinical diagnosis of another inflammatory connective tissue disease
- Has any active infections, a serious infection within the past 3 months, or chronic bacterial infection
- Is a current smoker or smoking within 6 months of screening
- Has any concomitant medical conditions that, in the opinion of the investigator, might place them in unacceptable risk for participation in the study
- Meets the protocol criteria for important laboratory exclusion criteria
Plan d'étude
Comment l'étude est-elle conçue ?
Détails de conception
- Objectif principal: Traitement
- Répartition: Randomisé
- Modèle interventionnel: Affectation parallèle
- Masquage: Quadruple
Armes et Interventions
Groupe de participants / Bras |
Intervention / Traitement |
|---|---|
|
Expérimental: Tulisokibart
Tulisokibart IV administered by IV infusion |
Tulisokibart administered at timepoints as directed by the protocol
Autres noms:
CDx+ or CDx- |
|
Comparateur placebo: Placebo
Placebo administered by IV infusion |
Placebo CDx+ or CDx- |
Que mesure l'étude ?
Principaux critères de jugement
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Number of Participants who Experience an Adverse Event (AE)
Délai: Up to Week 50
|
An AE is any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug related. The number of participants who experience an AE will be reported. |
Up to Week 50
|
|
Number of Participants who Experience a Serious Adverse Event (SAE)
Délai: Up to Week 50
|
An AE is any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug related. The number of participants who experience an SAE will be reported. |
Up to Week 50
|
|
Number of Participants who Discontinue due to an AE
Délai: Up to Week 50
|
An AE is any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug related. The number of participants who discontinue due to an AE will be reported. |
Up to Week 50
|
|
Change from Baseline in the Annual Rate of Change in Forced Vital Capacity (FVC) at Week 50
Délai: Baseline and up to Week 50
|
FVC, as measured in milliliters by spirometry, is the amount of air forcibly exhaled from the lungs after taking the deepest breath possible. |
Baseline and up to Week 50
|
Mesures de résultats secondaires
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Change from Baseline in FVC at Week 50
Délai: Baseline and Week 50
|
FVC, as measured in milliliters by spirometry, is the amount of air forcibly exhaled from the lungs after taking the deepest breath possible. |
Baseline and Week 50
|
|
Change from Baseline in High-Resolution Computer Tomography (HRCT) Quantitative Interstitial Lung Disease - Whole Lung (QILD-WL) at Week 50
Délai: Baseline and Week 50
|
QILD-WL will be measured as percent lung involvement using HRCT. |
Baseline and Week 50
|
|
Percentage of Participants with an Improvement in the Revised Composite Response Index in Systemic Sclerosis (CRISS) Score at Week 50
Délai: Baseline and Week 50
|
The Revised CRISS is a two-step process designed to evaluate the likelihood of improvement in early SSc. The first step assesses worsening or incident cases of internal organ involvement (scleroderma renal crisis, pulmonary arterial hypertension, congestive heart failure, ILD, severe gastrointestinal dysmotility requiring parenteral or enteral nutrition, and digital ischemia requiring hospitalization, gangrene, or amputation). The second step assesses changes from baseline in five core set measures: modified Rodnan skin score (mRSS), percent predicted forced vital capacity (FVC%), health assessment questionnaire-disability index (HAQ-DI), patient (PGA), and physician (PhGA) global assessments. |
Baseline and Week 50
|
|
Change from Baseline in Health Assessment Questionnaire Disability Index (HAQ-DI) at Week 50
Délai: Baseline and Week 50
|
HAQ is an instrument to assess physical function. It consists of 20 questions, covering eight types of activities. For each question, scores range from 0 to 3 (0 = without any difficulty; 1 = with some difficulty; 2 = with much difficulty or with assistance; 3 = unable to do). HAQ Disability Index (HAQ-DI) score is the average of the highest score in each of the eight categories. |
Baseline and Week 50
|
|
Change from Baseline in Living with Pulmonary Fibrosis (L-PF) Quality of Life (QoL) Outcome at Week 50
Délai: Baseline and Week 50
|
The L-PF is a questionnaire designed to assess the quality of life of patients with pulmonary fibrosis. It contains 44 questions (items) split into two modules, 23 which assess symptoms (including shortness of breath, cough, and fatigue) and 21 which assess impacts to quality of life. Individual items are scored on a 5-point scale (0 = Not at All to 4 = Extremely). Overall scores range from 0 to 100 with higher scores indicating a greater impairment. |
Baseline and Week 50
|
Collaborateurs et enquêteurs
Les enquêteurs
- Directeur d'études: Prometheus Biosciences, Clinical Trials Call Center
Publications et liens utiles
Liens utiles
Dates d'enregistrement des études
Dates principales de l'étude
Début de l'étude (Réel)
Achèvement primaire (Réel)
Achèvement de l'étude (Estimé)
Dates d'inscription aux études
Première soumission
Première soumission répondant aux critères de contrôle qualité
Première publication (Réel)
Mises à jour des dossiers d'étude
Dernière mise à jour publiée (Réel)
Dernière mise à jour soumise répondant aux critères de contrôle qualité
Dernière vérification
Plus d'information
Termes liés à cette étude
Termes MeSH pertinents supplémentaires
Autres numéros d'identification d'étude
- 7240-007
- PR200-104 (Autre identifiant: PrometheusBio)
- 2021-005206-10 (Numéro EudraCT)
- MK-7240-007 (Autre identifiant: MSD)
- U1111-1309-6150 (Identificateur de registre: UTN)
- 2023-509743-27-00 (Identificateur de registre: EU CT)
- 2023 (Subvention/contrat des NIH des États-Unis)
Plan pour les données individuelles des participants (IPD)
Prévoyez-vous de partager les données individuelles des participants (DPI) ?
Description du régime IPD
https://trialstransparency.msdclinicaltrials.com/pdf/ProcedureAccessClinicalTrialData.pdf
Informations sur les médicaments et les dispositifs, documents d'étude
Étudie un produit pharmaceutique réglementé par la FDA américaine
Étudie un produit d'appareil réglementé par la FDA américaine
Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .